TY  - JOUR
AU  - Rodríguez-Carreiro, Santiago
AU  - Muñoz, Eduardo
AU  - Fernández-Ruiz, Javier
AU  - Navarro González De Mesa, Elisa
PY  - 2023
DO  - 10.3390/brainsci13091272
UR  - https://hdl.handle.net/20.500.14352/103460
T2  - Brain Sciences
AB  - Background: A cannabigerol aminoquinone derivative, so-called VCE-003.2, has been found to behave as a neuroprotective agent (administered both i.p. and orally) in different experimental models of Parkinson’s disease (PD) in mice. These effects...
LA  - eng
M2  - 1272
PB  - MPDI
KW  - VCE-003.2
KW  - L-DOPA/benserazide
KW  - Parkinson’s disease
KW  - 6-OHDA-lesioned mice
KW  - Cannabinoids; PPAR-γ
TI  - The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy
TY  - journal article
VL  - 13
ER  -